Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Deep Spatial Sequencing Revealing Differential Immune Responses in Human Hepatocellular Carcinoma

ABSTRACT: Deep Spatial Sequencing Revealing Differential Immune Responses in Human Hepatocellular Carcinoma

PROVIDER: PRJNA1193588 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31591461.fastq.gz	Fastqsanger.gz
	SRR31591462.fastq.gz	Fastqsanger.gz
	SRR31591463.fastq.gz	Fastqsanger.gz
	SRR31591464.fastq.gz	Fastqsanger.gz
	SRR31591465.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Deep Spatial Sequencing Revealing Differential Immune Responses in Human Hepatocellular Carcinoma [AVITI]

Project description:Deep Spatial Sequencing Revealing Differential Immune Responses in Human Hepatocellular Carcinoma [AVITI]

| PRJNA1193594 | ENA

Deep Spatial Sequencing Revealing Differential Immune Responses in Human Hepatocellular Carcinoma [NextSeq]

Project description:Deep Spatial Sequencing Revealing Differential Immune Responses in Human Hepatocellular Carcinoma [NextSeq]

| PRJNA1193592 | ENA

Deep Spatial Sequencing Revealing Differential Immune Responses in Human Hepatocellular Carcinoma [AVITI]

Project description:Hepatocellular carcinoma (HCC) is one of the most lethal cancers for humans. HCC is highly heterogeneous. In this study, we performed ultra-depth (~1 million reads per spot) spatial sequencing on a case of HCC. Sixteen distinct spatial expression clusters were identified. Each of these clusters was spatially contiguous and had distinct gene expression patterns. In contrast, benign liver tissues showed minimal heterogeneity in terms of gene expression. Numerous immune cell-enriched spots were identified in both HCC and benign liver regions. Cells adjacent to these immune cell-enriched spots showed significant alterations in their gene expression patterns. Interestingly, the responses of HCC cells to the nearby immune cells were significantly more intense and broader, while the responses of benign liver cells to immune cells were somewhat narrow and muted, suggesting an innate difference in immune cell activities towards HCC cells in comparison with benign liver cells. When standard-depth sequencing was performed, significant numbers of genes and pathways that were associated with these changes disappeared. Qualitative differences in some pathways were also found. These results suggest that deep spatial sequencing may help to uncover previously unidentified mechanisms of liver cancer development.

2025-04-16 | GSE283405 | GEO

Deep Spatial Sequencing Revealing Differential Immune Responses in Human Hepatocellular Carcinoma [NextSeq]

2025-04-16 | GSE283404 | GEO

Deep Spatial Sequencing Revealing Differential Immune Responses in Human Hepatocellular Carcinoma

Project description:This SuperSeries is composed of the SubSeries listed below.

2025-04-16 | GSE283406 | GEO

Human hepatocellular carcinoma

Project description:Spatial transcriptome on human hepatocellular carcinoma

| PRJEB62485 | ENA

Spatial tissue proteomics quantifies inter- and intra-tumor heterogeneity in hepatocellular carcinoma

Project description:The inter-patient variability of tumor proteomes has been investigated on a large scale but many tumors display also intra-tumoral heterogeneity (ITH) regarding morphological and genetic features. To what extent the local proteome of tumors intrinsically differs remains largely unknown. Here, we used hepatocellular carcinoma (HCC) as a model system, to quantify both inter- and intra-tumor heterogeneity across human patient specimens with spatial resolution. We first defined proteomic features that robustly distinguish neoplastic from the directly adjacent non-neoplastic tissue by integrating proteomic data from human patient samples and genetically defined mouse models with available gene expression data. We then demonstrated the existence of intra-tumoral variations in protein abundance that re-occur across different patient samples, and affect clinically relevant proteins, even in the absence of obvious morphological differences or genetic alterations. Our work demonstrates the suitability and the benefits of using mass spectrometry based proteomics to analyze diagnostic tumor specimens with spatial resolution

2018-01-24 | PXD007052 | Pride

Deep targeted sequencing of multiregional sampling in hepatocellular carcinoma

Project description:The purpose of this experiment of high-coverage DNA sequencing of 58 frequently mutated genes in hepatocellular carcinoma (HCC) is to confirm clonal distribution of the known HCC drivers in samples corresponding to multiple regions of a tumor.

2020-01-16 | E-MTAB-5899 | biostudies-arrayexpress

Ultra-deep sequencing of plasma DNA identifies druggable mutations in hepatocellular carcinoma

Project description:The purpose of the study is to detect somatic mutations in hepatocellular carcinoma using circulating free-DNA. We used deep-sequencing data of a panel of 60 commonly mutated genes in hepatocellular carcinoma.

2018-04-29 | E-MTAB-5123 | biostudies-arrayexpress

Spatial omics based machine learning (SOML) algorithms for the early detection of hepatocellular carcinoma.

Project description:Hepatocellular carcinoma (HCC) is the seventh most common cancer in the world and accounts for over 800,000 deaths annually, making it the second most lethal cancer. Poor chemotherapeutic agents against HCC have necessitated the importance of early detection and surgical intervention in patient management. However, the search for biomarkers of HCC have proved difficult, as serum and tissue proteomics, transcriptomics and genomics have proved inconclusive. We have utilized a novel spatial-omics based glycan imaging method to identify glycan changes that occur directly in HCC tissue. Glycan changes included branched, fucosylated and high mannose glycan. Importantly, using matching serum samples, we were able to identify the glycans that are altered in tissue and also in the serum of individuals with HCC. Glycoproteomics was used to identify the proteins containing these glycan structures. To translate these findings, we utilized a novel multi-plexed antibody panel based glycan imaging method, which allowed us to examine all the glycans associated with the identified glycoproteins. These glycan changes, found in serum, and directly associated with the tumor, were used to create a diagnostic algorithm to detect HCC. These spatial omics based, machine learning (SOML) algorithms were tested in a discovery set (n=201) and an external validation set (n=192). AUROC values ranged from 0.95 in the discovery set and 0.91 in the independent external validation set. In conclusion, we present the development and application of a new biomarker platform that can be used to examine the glycans associated with disease.

2025-05-06 | PXD047546 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data